Literature DB >> 22956346

Kisspeptin-10 stimulation of gonadotrophin secretion in women is modulated by sex steroid feedback.

J T George1, R A Anderson, R P Millar.   

Abstract

STUDY QUESTION: Does sex-steroid feedback influence gonadotrophin responses to kisspeptin-10? SUMMARY ANSWER: Gonadotrophin response to kisspeptin-10 is enhanced in sex-steroid deficient post-menopausal women and suppressed in women taking pharmacological doses of exogenous estrogen and progestogen. WHAT IS KNOWN ALREADY: Kisspeptin, a novel hypothalamic neuropeptide, stimulates gonadotrophin secretion by stimulating GnRH secretion and has been shown in animal models to play a pivotal role in mediating sex steroid feedback. As estrogen feedback occurs at both the hypothalamus and the pituitary levels, we hypothesized that the stimulatory effect of kisspeptin-10 in women would be dependent on prevailing sex steroid milieu. STUDY DESIGN, SIZE, DURATION: An experimental study of a novel neuropeptide in women-10 in the early follicular phase, 6 post-menopausal and 8 taking sex-steroid contraceptives (combined pill, n = 4; progestogen implants, n = 4) with suppressed LH secretion. Gonadotrophin secretion was followed for 60 min after kisspeptin administration. METHODS AND PARTICIPANTS: The gonadotrophin response to intravenous kisspeptin-10 (0.3 µg/kg) in women in the early follicular phase was compared with that in the presence of low endogenous sex steroids/high gonadotrophin secretion (post-menopausal women) and in women taking sex-steroid contraceptives (combined pill, n = 4; progestogen implants, n = 4) with suppressed LH secretion. Area under the curve (AUC) of gonadotrophin secretion sampled at 15 min intervals over 60 min before and after kisspeptin-10 was analysed. MAIN RESULTS AND ROLE OF CHANCE: Kisspeptin-10 stimulated LH secretion in follicular (ΔAUC 2.3 ± 0.8 IU/l h, P = 0.009), post-menopausal (5.3 ± 0.9 IU/l h P 0.002) and progestogen (2.6 ± 0.8 IU/l h P 0.05) groups but not in women taking combined pill (0.9 ± 0.4 IU/l h P 0.13). FSH secretion was significantly increased only in post-menopausal women (ΔAUC 2.6 ± 0.8 IU/l h P = 0.03) with changes of <0.5 IU/l h observed in the other three groups. Both LH and FSH responses in post-menopausal women were significantly larger than the other groups (one-way ANOVA analysis of ΔAUC; LH (P = 0.012) and FSH (P = 0.001)]. LIMITATIONS, REASONS FOR CAUTION: This study only assessed acute responses to an intravenous bolus of kisspeptin-10 administration, and the impact of continuous exposure to kisspeptin-10 on LH pulse frequency in women remains to be studied to fully understand the translational potential. WIDER IMPLICATIONS OF THE
FINDINGS: Gonadotrophin secretion in women is stimulated by kisspeptin-10. These results suggest that the pituitary gonadotrope is a functionally important locus of estrogen feedback in women and also inform potential translational applications of kisspeptin in reproductive endocrine disorders. STUDY FUNDING: Medical Research Council (UK). COMPETING INTERESTS: None.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22956346     DOI: 10.1093/humrep/des326

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  16 in total

1.  Continuous Kisspeptin Administration in Postmenopausal Women: Impact of Estradiol on Luteinizing Hormone Secretion.

Authors:  Margaret F Lippincott; Yee-Ming Chan; Dianali Rivera Morales; Stephanie B Seminara
Journal:  J Clin Endocrinol Metab       Date:  2017-06-01       Impact factor: 5.958

Review 2.  Kisspeptin and the hypothalamic control of reproduction: lessons from the human.

Authors:  Jyothis T George; Stephanie B Seminara
Journal:  Endocrinology       Date:  2012-09-26       Impact factor: 4.736

3.  Downregulation of leptin receptor and kisspeptin/GPR54 in the murine hypothalamus contributes to male hypogonadism caused by high-fat diet-induced obesity.

Authors:  Lingling Zhai; Jian Zhao; Yiming Zhu; Qiannan Liu; Wenhua Niu; Chengyin Liu; Yi Wang
Journal:  Endocrine       Date:  2018-06-13       Impact factor: 3.633

Review 4.  Current and future applications of GnRH, kisspeptin and neurokinin B analogues.

Authors:  Robert P Millar; Claire L Newton
Journal:  Nat Rev Endocrinol       Date:  2013-07-02       Impact factor: 43.330

5.  Divergent responses to kisspeptin in children with delayed puberty.

Authors:  Yee-Ming Chan; Margaret F Lippincott; Temitope O Kusa; Stephanie B Seminara
Journal:  JCI Insight       Date:  2018-04-19

Review 6.  The kisspeptin-GnRH pathway in human reproductive health and disease.

Authors:  Karolina Skorupskaite; Jyothis T George; Richard A Anderson
Journal:  Hum Reprod Update       Date:  2014-03-09       Impact factor: 15.610

7.  Interactions Between Neurokinin B and Kisspeptin in Mediating Estrogen Feedback in Healthy Women.

Authors:  Karolina Skorupskaite; Jyothis T George; Johannes D Veldhuis; Robert P Millar; Richard A Anderson
Journal:  J Clin Endocrinol Metab       Date:  2016-09-16       Impact factor: 5.958

8.  Neurokinin B Regulates Gonadotropin Secretion, Ovarian Follicle Growth, and the Timing of Ovulation in Healthy Women.

Authors:  Karolina Skorupskaite; Jyothis T George; Johannes D Veldhuis; Richard A Anderson
Journal:  J Clin Endocrinol Metab       Date:  2018-01-01       Impact factor: 5.958

9.  Exogenous kisspeptin administration as a probe of GnRH neuronal function in patients with idiopathic hypogonadotropic hypogonadism.

Authors:  Yee-Ming Chan; Margaret F Lippincott; James P Butler; Valerie F Sidhoum; Cindy X Li; Lacey Plummer; Stephanie B Seminara
Journal:  J Clin Endocrinol Metab       Date:  2014-12       Impact factor: 5.958

10.  Subcutaneous infusion of kisspeptin-54 stimulates gonadotrophin release in women and the response correlates with basal oestradiol levels.

Authors:  Shakunthala Narayanaswamy; Channa N Jayasena; Noel Ng; Risheka Ratnasabapathy; Julia K Prague; Deborah Papadopoulou; Ali Abbara; Alexander N Comninos; Paul Bassett; Stephen R Bloom; Johannes D Veldhuis; Waljit S Dhillo
Journal:  Clin Endocrinol (Oxf)       Date:  2015-12-17       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.